Registered number
14614068
KHADIJA PHARMS LTD
Filleted Accounts
31 March 2024
KHADIJA PHARMS LTD
Registered number: 14614068
Balance Sheet
as at 31 March 2024
Notes 2024
£
Fixed assets
Tangible assets 3 900
Current assets
Debtors 4 1,620
Cash at bank and in hand 7,007
8,627
Creditors: amounts falling due within one year 5 (7,066)
Net current assets 1,561
Net assets 2,461
Capital and reserves
Called up share capital 100
Profit and loss account 2,361
Shareholders' funds 2,461
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
KHADIJA SAID
Director
Approved by the board on 24 October 2024
KHADIJA PHARMS LTD
Notes to the Accounts
for the year ended 31 March 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Plant and machinery over 5 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 Employees 2024
Number
Average number of persons employed by the company 1
3 Tangible fixed assets
Plant and machinery etc
£
Cost
Additions 1,000
At 31 March 2024 1,000
Depreciation
Charge for the year 100
At 31 March 2024 100
Net book value
At 31 March 2024 900
4 Debtors 2024
£
Trade debtors 1,620
5 Creditors: amounts falling due within one year 2024
£
Trade creditors 1,183
Corporation Tax 8,599
Directors Loan (2,716)
7,066
6 Controlling party
The company is under the full control of the director, by virtue of them oowning the fully issued share capital.
7 Other information
KHADIJA PHARMS LTD is a private company limited by shares and incorporated in England. Its registered office is:
Flat 33 The Brookdales
Bridge Lane
London
ENGLAND
NW11 9JU
KHADIJA PHARMS LTD 14614068 false 2023-04-01 2024-03-31 2024-03-31 VT Final Accounts July 2024 KHADIJA SAID No description of principal activity 14614068 2023-04-01 2024-03-31 14614068 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 14614068 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 14614068 bus:Director40 2023-04-01 2024-03-31 14614068 1 2023-04-01 2024-03-31 14614068 2 2023-04-01 2024-03-31 14614068 countries:England 2023-04-01 2024-03-31 14614068 bus:FRS102 2023-04-01 2024-03-31 14614068 bus:FilletedAccounts 2023-04-01 2024-03-31 14614068 2024-03-31 14614068 core:WithinOneYear 2024-03-31 14614068 core:ShareCapital 2024-03-31 14614068 core:RetainedEarningsAccumulatedLosses 2024-03-31 14614068 2023-03-31 iso4217:GBP xbrli:pure